Tadalafil

證據等級: L5

預測適應症: 8 個

TADALAFIL: From Erectile Dysfunction / Pulmonary Arterial Hypertension to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Tadalafil is a selective PDE5 inhibitor widely approved for erectile dysfunction, pulmonary arterial hypertension (PAH), and benign prostatic hyperplasia. The TxGNN model assigns its highest score to Ambras Type Hypertrichosis Universalis Congenita, with 0 clinical trials and 0 supporting publications — and the mechanistic evidence strongly suggests this is a false positive: tadalafil is itself a documented cause of excessive hair growth (trichomegaly) as an adverse effect, meaning the model has likely learned a drug–side-effect association and misclassified it as a treatment signal.

Quick Overview

Item	Content
Original Indication	Erectile dysfunction, pulmonary arterial hypertension, benign prostatic hyperplasia (known from pharmaceutical literature; no Italy regulatory record available)
Predicted New Indication	Ambras Type Hypertrichosis Universalis Congenita
TxGNN Prediction Score	99.98%
Evidence Level	L5
Italy Market Status	✗ Not Marketed (0 registered licenses in data)
Number of Authorizations	0
Recommended Decision	Hold

⚠️ Data Note: Tadalafil (Cialis®, Adcirca®) is commercially available across the EU, including Italy. The zero-license result likely reflects a data retrieval gap rather than true absence from the Italian market. Regulatory confirmation via AIFA should be obtained before drawing conclusions about market status.

Why is This Prediction Reasonable?

Detailed mechanism of action data is not present in the Evidence Pack. Based on established pharmaceutical knowledge, Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), preventing degradation of cyclic guanosine monophosphate (cGMP). The resulting rise in intracellular cGMP promotes smooth muscle relaxation and vasodilation — the basis for its approved uses in penile vasculature (erectile dysfunction), pulmonary vasculature (PAH), and prostatic smooth muscle (BPH).

Ambras type hypertrichosis universalis congenita is a rare autosomal dominant disorder caused by mutations in the TRPS1 gene. It is characterized by diffuse, excessive growth of terminal hair over the entire body surface. The pathology is rooted in abnormal hair follicle development driven by TRPS1 dysfunction, with no known intersection with the PDE5/cGMP signaling pathway.

The mechanistic direction here is, in fact, reversed: trichomegaly (excessive eyelash elongation) is a recognized adverse effect of PDE5 inhibitors including tadalafil, documented in multiple pharmacovigilance reports. This means that elevated cGMP likely promotes hair follicle growth rather than suppressing it — precisely the opposite of what would be needed to treat hypertrichosis. The TxGNN model appears to have encoded this drug–side-effect co-occurrence as a positive treatment association, a known failure mode in knowledge graph–based repurposing algorithms. This prediction should be classified as a false positive and excluded from further development.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Italy Market Information

No Italy regulatory authorizations are on record for Tadalafil in the current dataset. As noted above, this is likely a data gap. Tadalafil is EU-authorized under Cialis® (erectile dysfunction, BPH) and Adcirca® (pulmonary arterial hypertension); AIFA records should be queried directly to confirm the active authorization list.

Safety Considerations

Please refer to the package insert for safety information.

Additional note relevant to the predictions in this pack: PDE5 inhibitors are known to trigger headache and, in documented cases, migraine aura via the NO–cGMP pathway activating the trigeminovascular system. One case report (PMID 17059442) records tadalafil-associated typical migraine aura without headache. This is directly relevant because rank-8 prediction (migraine with brainstem aura) represents a safety risk, not a treatment opportunity.

Conclusion and Next Steps

Decision: Hold

Rationale: All top-ranked TxGNN predictions for tadalafil exhibit a systematic pattern of false positives — hair-related disorders (ranks 1, 2, 5, 6) that reflect a drug–adverse-effect inversion, a structural brain malformation with no mechanistic link (rank 4), a periodontal condition where 20 retrieved publications are disease-general literature entirely unrelated to tadalafil (rank 3), and a migraine subtype where the sole relevant publication documents tadalafil as the cause of the aura (rank 8). None of the top 8 predictions constitutes a viable repurposing candidate based on current evidence.

The one direction worth formal investigation:

Rank 7 — kyphoscoliotic heart disease — is the only prediction with an indirect but biologically coherent rationale: severe thoracic kyphoscoliosis can cause restrictive lung disease → chronic hypoxia → secondary pulmonary arterial hypertension, and tadalafil (Adcirca®) is FDA- and EMA-approved for PAH. While no dedicated clinical trials exist for this subgroup, tadalafil's use in scoliosis-associated PAH falls within the scope of its approved mechanism.

To proceed, the following is needed:

Data gap remediation: Retrieve MOA data from DrugBank API (DG002) and package insert warnings/contraindications (DG001) to enable a complete safety evaluation.
AIFA regulatory verification: Confirm current Tadalafil authorization status in Italy (Cialis® and Adcirca® are expected to be listed; absence from current data is likely a retrieval error).
Model audit: Flag the tadalafil predictions as a test case for PDE5i false-positive filtering. The model appears to systematically confuse side-effect graph edges with therapeutic edges for this drug class. Consider adding a side-effect exclusion layer to the post-processing pipeline.
Research question (rank 7 only): Design a retrospective case series or sub-group analysis examining PDE5 inhibitor use in patients with kyphoscoliosis-associated PAH, using existing PAH registry data.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.